Related references
Note: Only part of the references are listed.Single-Cell RNA-Seq Identifies Potentially Pathogenic B Cell Populations That Uniquely Circulate in Patients with Chronic Gvhd
Jonathan C. Poe et al.
BLOOD (2019)
Distinct Effector B Cells Induced by Unregulated Toll-like Receptor 7 Contribute to Pathogenic Responses in Systemic Lupus Erythematosus
Scott A. Jenks et al.
IMMUNITY (2018)
Ibrutinib for chronic graft-versus-host disease after failure of prior therapy
David Miklos et al.
BLOOD (2017)
Unbalanced recovery of regulatory and effector T cells after allogeneic stem cell transplantation contributes to chronic GVHD
Ana C. Alho et al.
BLOOD (2016)
Phase-1/-2 study of pomalidomide in chronic GvHD
I. Pusic et al.
BONE MARROW TRANSPLANTATION (2016)
A Randomized Phase II Crossover Study of Imatinib or Rituximab for Cutaneous Sclerosis after Hematopoietic Cell Transplantation
Sally Arai et al.
CLINICAL CANCER RESEARCH (2016)
Efficacy, durability, and response predictors of low-dose interleukin-2 therapy for chronic graft-versus-host disease
John Koreth et al.
BLOOD (2016)
Differential effects of lenalidomide during plasma cell differentiation
Michel Jourdan et al.
ONCOTARGET (2016)
Imatinib Mesylate for the Treatment of Steroid-Refractory Sclerotic-Type Cutaneous Chronic Graft-versus-Host Disease
Kristin Baird et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2015)
CD19+CD21low B Cells and CD4+CD45RA+CD31+ T Cells Correlate with First Diagnosis of Chronic Graft-versus-Host Disease
Hildegard T. Greinix et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2015)
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III. The 2014 Biomarker Working Group Report
Sophie Paczesny et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2015)
Increasing Incidence of Chronic Graft-versus-Host Disease in Allogeneic Transplantation: A Report from the Center for International Blood and Marrow Transplant Research
Sally Arai et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2015)
Measuring Therapeutic Response in Chronic Graft-versus-Host Disease. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. The 2014 Response Criteria Working Group Report
Stephanie J. Lee et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2015)
How we treat chronic graft-versus-host disease
Mary E. D. Flowers et al.
BLOOD (2015)
Failure-free survival after initial systemic treatment of chronic graft-versus-host disease
Yoshihiro Inamoto et al.
BLOOD (2014)
Lenalidomide inhibits the proliferation of CLL cells via a cereblon/p21WAF1/Cip1-dependent mechanism independent of functional p53
Jessie-F. Fecteau et al.
BLOOD (2014)
Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4CRBN
Anita K. Gandhi et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
A sensitive and robust HPLC assay with fluorescence detection for the quantification of pomalidomide in human plasma for pharmacokinetic analyses
Shandiz Shahbazi et al.
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS (2014)
Comparative analysis of FoxP3+ regulatory T cells in the target tissues and blood in chronic graft versus host disease
M. M. Imanguli et al.
LEUKEMIA (2014)
Prevalence of isolated joint involvement in chronic graft-versus-host disease: comment on the article by Inamoto et al
Zoya Kuzmina et al.
ARTHRITIS & RHEUMATOLOGY (2014)
Assessment of Joint and Fascia Manifestations in Chronic Graft-Versus-Host Disease
Yoshihiro Inamoto et al.
ARTHRITIS & RHEUMATOLOGY (2014)
National Institutes of Health Chronic Graft-versus-Host Disease Staging in Severely Affected Patients: Organ and Global Scoring Correlate with Established Indicators of Disease Severity and Prognosis
Kristin Baird et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2013)
Long-term outcome and prospective validation of NIH response criteria in 39 patients receiving imatinib for steroid-refractory chronic GVHD
Attilio Olivieri et al.
BLOOD (2013)
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial
Jesus San Miguel et al.
LANCET ONCOLOGY (2013)
Low-Dose Interleukin-2 Therapy Restores Regulatory T Cell Homeostasis in Patients with Chronic Graft-Versus-Host Disease
Ken-ichi Matsuoka et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
Pomalidomide is effective for prevention and treatment of experimental skin fibrosis
Simon Weingaertner et al.
ANNALS OF THE RHEUMATIC DISEASES (2012)
Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide
A. Lopez-Girona et al.
LEUKEMIA (2012)
Consensus Conference on Clinical Practice in Chronic GVHD: Second-Line Treatment of Chronic Graft-versus-Host Disease
Daniel Wolff et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2011)
How I conduct a comprehensive chronic graft-versus-host disease assessment
Paul A. Carpenter
BLOOD (2011)
Interleukin-2 and Regulatory T Cells in Graft-versus-Host Disease
John Koreth et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Combined CD4+ Donor Lymphocyte Infusion and Low-Dose Recombinant IL-2 Expand FOXP3+ Regulatory T Cells following Allogeneic Hematopoietic Stem Cell Transplantation
Emmanuel Zorn et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2009)
Pomalidomide (CC4047) Plus Low-Dose Dexamethasone As Therapy for Relapsed Multiple Myeloma
Martha Q. Lacy et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Elevated numbers of immature/transitional CD2I- B lymphocytes and deficiency of memory CD27+ B cells identify patients with active chronic graft-versus-host disease
Hildegard T. Greinix et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2008)
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma
A. Palumbo et al.
LEUKEMIA (2008)
Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. Response Criteria Working Group report
SZ Pavletic et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2006)
National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report
AH Filipovich et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2005)
Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma
SA Schey et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Thalidomide after allogeneic haematopoietic stem cell transplantation: activity in chronic but not in acute graft-versus-host disease
S Kulkarni et al.
BONE MARROW TRANSPLANTATION (2003)
Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs
PH Schafer et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2003)
Protective antitumor immunity induced by a costimulatory thalidomide analog in conjunction with whole tumor cell vaccination is mediated by increased Th1-type immunity
K Dredge et al.
JOURNAL OF IMMUNOLOGY (2002)
Randomized clinical trial of thalidomide, cyclosporine, and prednisone versus cyclosporine and prednisone as initial therapy for chronic graft-versus-host disease
M Arora et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2001)
Response to thalidomide therapy in refractory chronic graft-versus-host disease
PV Browne et al.
BONE MARROW TRANSPLANTATION (2000)
Share Paper
